- Posted April 08, 2014
- Tweet This | Share on Facebook
Supreme Court takes up drug company dispute
![](/Content/LegalNews/images/article_db_image1.jpg)
WASHINGTON (AP) -- The Supreme Court is wading into a patent dispute between rival pharmaceutical companies over a multiple sclerosis treatment.
The justices agreed last week to hear an appeal from Teva Pharmaceutical Industries Ltd., which claims the U.S. Court of Appeals for the Federal Circuit wrongly overturned five of its patents for the drug Copaxone.
The appeals court ruling would allow rivals Mylan Inc., Momenta Pharmaceuticals Inc. and Sandoz, Inc., to start selling generic versions of the drug later this year, after the remaining patents on the drug expire.
A federal district court had earlier ruled in Teva's favor and upheld the patents. Teva says the federal circuit should have deferred to factual findings made in the district court.
The justices will hear the case in the fall.
Published: Tue, Apr 8, 2014
headlines Oakland County
headlines National
- Michelle Behnke looks to build community and strengthen the ABA with new strategic plan
- ACLU and BigLaw firm use ‘Orange is the New Black’ in hashtag effort to promote NY jail reform
- New research about legal operations is ‘at a crossroads,’ consortium leaders say
- You were probably not taught to market yourself; now what?
- Which BigLaw firms pay the highest starting salary?
- Netflix’s true-crime documentary about woman stalking man flows like book you can’t put down